Cluster 1 had the highest mortality risk (HR 2.03, 95% CI 1.552.67, p 25cm HO
Widely used in research settings requiring complex compound combinations
DISSECTION P938 - ESOC25-2421 CADASIL Argentine Registry (CADASILar): Establishing a Harmonized Clinical Protocol preliminary data Julieta Rosales 1 , Carolina Ardohain 2 , Juan Lopez 3 , Fabio Gonzalez 4 , Julian Alonso 5 , Valentin Selvaggi 6 , Diana Cristalli 7 , Ismael Calandri 2 1 Clinica Sagrada Familia-ENERI, Buenos Aires, Argentina, 2 FLENI, Buenos Aires, Argentina, 3 Sanatorio Los Arcos, Buenos Aires, Argentina, 4 Hospital Italiano de Bs As, Buenos Aires, Argentina, 5 Hospital Posadas, Buenos Aires, Argentina, 6 Hospital Ramos Meja, Buenos Aires, Argentina, 7 Centro Jesi, Buenos Aires, Argentina Background and Aims: CADASIL, a leading monogenic small vessel disease caused by NOTCH3 mutations, manifests with migraines, strokes, and cognitive decline
Users should always review ingredients and consult healthcare professionals before mixing glutathione with other treatments
What the Human Evidence Actually Shows Sadly, we currently dont have massive Phase 3 trials comparing GHK-Cu head-to-head with Finasteride in 5,000 men
